NCT05463640 is a Phase 1 clinical trial of ADGRE2 CAR-T in AML, sponsored by Zhejiang University.

Who is sponsoring NCT05463640?

NCT05463640 is sponsored by Zhejiang University.

What drugs are being tested in NCT05463640?

Interventions in NCT05463640: ADGRE2 CAR-T.

Is NCT05463640 still recruiting?

NCT05463640 is currently status unknown. Last updated 19 July 2022.

Last reviewed 2022-07-19 · How we verify

NCT05463640

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Safety and Efficacy of ADGRE2 CAR-T in Patients With R/R AML

Status unknown Phase 1 Last updated 19 July 2022

What this trial tests

Phase 1 trial testing ADGRE2 CAR-T in AML in 20 participants. Status unknown.

Timeline

2 August 2022

Primary endpoint
2 August 2024

2 August 2025

Quick facts

Lead sponsor	Zhejiang University
Phase	Phase 1
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	2 August 2022
Primary completion	2 August 2024
Estimated completion	2 August 2025
Sites	1 location across China

Drugs / interventions tested

ADGRE2 CAR-T — full drug profile →

Conditions studied

AML — all drugs for AML →

Sponsor

Zhejiang University

Who can join

Adults 2 to 70, any sex, with AML. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label, phase I study to assess the safety and efficacy of ADGRE2 CAR-T in patients with relapsed and refractory acute myeloid leukemia

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

CAR-T cell therapy for cancer: current challenges and future directions.
Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, et al · · 2025 · cited 81× · PMID 40610404 · DOI 10.1038/s41392-025-02269-w
Recent Advances in Immune-Based Therapies for Acute Myeloid Leukemia.
Restelli C, Ruella M, Paruzzo L, Tarella C, et al · · 2024 · cited 36× · PMID 38904305 · DOI 10.1158/2643-3230.bcd-23-0202
Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M, Nguyen A, Hussain A, Ammad-Ud-Din M, et al · · 2023 · cited 28× · PMID 37168849 · DOI 10.3389/fimmu.2023.1152457
Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers.
Gu X, Zhang Y, Zhou W, Wang F, et al · · 2024 · cited 21× · PMID 39061100 · DOI 10.1186/s40164-024-00542-2
Targets for chimeric antigen receptor T-cell therapy of acute myeloid leukemia.
Schorr C, Perna F. · · 2022 · cited 21× · PMID 36605213 · DOI 10.3389/fimmu.2022.1085978
A perspective of immunotherapy for acute myeloid leukemia: Current advances and challenges.
Chen Y, Wang J, Zhang F, Liu P. · · 2023 · cited 13× · PMID 37153761 · DOI 10.3389/fphar.2023.1151032
Recent advances in CAR-T cell therapy for acute myeloid leukaemia.
Gao C, Li X, Xu Y, Zhang T, et al · · 2024 · cited 8× · PMID 38712978 · DOI 10.1111/jcmm.18369
Recent advances of CAR-T cells in acute myeloid leukemia.
Deng H, Wang Q, Tong X, Cui Z, et al · · 2025 · cited 5× · PMID 40144774 · DOI 10.1177/20406207251326802

Verify or expand the search:

Other recruiting trials for AML

Currently open trials in the same condition.

NCT06611839 — Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML · Phase 1, PHASE2 · recruiting
NCT07163728 — Leptin: A Marker for AML Chemo-Sensitivity · recruiting
NCT06973668 — A Randomized Study to Compare Post-transplant Cyclophosphamide, Sirolimus, Ruxolitinib and Post-transplant Cyclophospham · Phase 2 · recruiting
NCT07126782 — The Efficacy and Safety Assessment of Allogeneic γδ T Cells in Patients With MRD-positive AML After Allo-HSCT · EARLY_PHASE1 · recruiting
NCT06717958 — Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute M · Phase 2 · recruiting

Other Zhejiang University trials

Trials by the same sponsor.

NCT07487402 — Safety and Efficacy of Metabolically Armed GPC3 CAR-T Cells Injection (Meta10-GPC3) in Patients With Unresectable Recurr · EARLY_PHASE1 · not yet recruiting
NCT07480044 — A Phase II Clinical Two-Stage Study of Transcranial Magnetic Stimulation in Preventing Postoperative Delirium in Elderly · NA · not yet recruiting
NCT07467005 — Video Double-Lumen Tube for Secondary Pulmonary Resection · NA · not yet recruiting
NCT07429461 — Clinical Study of SYNCAR-100 in the Treatment of Relapsed/Refractory Acute B-Lymphoblastic Leukemia · EARLY_PHASE1 · recruiting
NCT07240766 — HRS-4642 in Combination With Nimotuzumab and Chemotherapy for BRPC With KRAS G12D Mutation · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05463640 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Zhejiang University
Last refreshed: 19 July 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05463640.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing